Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. Adaptive clinical trials: overview 1
- Prof. Yu Shyr
-
2. Adaptive clinical trials: overview 2
- Prof. Yu Shyr
-
3. Bayesian adaptive designs for clinical trials
- Prof. Benjamin Saville
-
4. Adaptive clinical trial design: randomization
- Prof. Hao Liu
-
5. Adaptive designs for phase I trials 1
- Prof. Anastasia Ivanova
-
6. Adaptive designs for phase I trials 2
- Prof. Anastasia Ivanova
-
7. Case studies of adaptive early phase trials
- Prof. Daniel Normolle
-
8. Phase II clinical trials - traditional approaches
- Prof. Fei Ye
-
9. Phase II clinical trials - Bayesian methods
- Prof. Fei Ye
-
10. Seamless phase II/III trials
- Prof. Elizabeth Garrett-Mayer
- Mr. Nathaniel O’Connell
-
11. Frequentist approaches: sample size in adaptive clinical designs
- Prof. Tatsuki Koyama
-
14. Ethical issues in adaptive clinical trials
- Dr. Spencer Phillips Hey
-
15. Implementation of adaptive methods in early phase clinical trials
- Prof. Gina Petroni
-
16. Design early phase drug combination trials: methods
- Prof. Ying Yuan
-
17. Design early phase drug combination trials: software
- Prof. Ying Yuan
-
18. Adaptation in likelihood trials
- Prof. Jeffrey Blume
Printable Handouts
Navigable Slide Index
- Introduction
- Context and purpose of talk
- Perspective
- Issues for discussion
- Essential protocol information: study objectives
- Study objectives: endpoints
- Safety endpoint: Adverse events (AEs)
- Safety endpoints: dose limiting toxicity
- Safety summary measure: Max tolerated dose
- Beyond safety: additional endpoints
- Beyond safety: other summary measures
- Study objectives: assessment period
- Study objectives: analysis population
- Decision process: overall sample size
- Dose/dose combination levels (predefined)
- Decision process: dose levels
- Decision process: dose combination levels
- Dose/dose combination levels (not predefined)
- Decision process: cohort sample size
- Decision process: escalation/de-escalation method
- Decision process: starting/stopping the trial
- Simulation studies
- Simulation results
- Dose limiting toxicity: example (1)
- Dose limiting toxicity: example (2)
- Dose escalation decision paths
- Software/programs
- Bayesian CRM: simulation (1)
- Bayesian CRM: simulation (2)
- Bayesian CRM: implementation (1)
- Bayesian CRM: implementation (2)
- Clinical research management system (1)
- Clinical research management system (2)
- Example CRF entered into management system
- Example data export from management system
- Responsibility of personnel
- Safety assessment reviews & decision process (1)
- Safety assessment reviews & decision process (2)
- Data capture & data flow: audit trail
- Summary checklist
- Thank you
- References
Topics Covered
- Practical guidance on implementing adaptive designs in early-phase clinical trials
- Essential protocol information that leads to acceptance of the design and directs implementation
- Issues that need to be considered and addressed prior to starting an adaptive design
- Examples & general check list on designing and implementing early-phase adaptive designs
Talk Citation
Petroni, G. (2018, May 31). Implementation of adaptive methods in early phase clinical trials [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/XZIE3089.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Gina Petroni has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is Gina Petroni and I am the director of the division of
Translational Research and Applied Statistics in the School of
Medicine's Department of Public Health Sciences at the University of Virginia.
My topic of presentation today is "Implementation
of Adaptive Methods in Early Phase Clinical Trials".
0:24
For this talk, I am assuming that there is initial understanding of the phases of
clinical research with early phase
referring to studies that assess safety and dose finding.
In addition, I am assuming there is familiarity with adaptive trial methodology.
Both the statistical and medical literature abounds with reviews,
justifications and recommendations on the use of
more novel designs to efficiently and accurately
address the objectives of finding
appropriate doses or dose combinations to merit further research.
These recommended designs are often referred to as adapted designs and
are based upon the premise that as safety and other information are acquired.
The whole of the information should be used to guide
those recommendations for future study participants.
Use of these model-based designs remains infrequent.
This can be attributed to several causes
including a poor understanding from clinicians and reviewers
in how these designs actually work and how best
to evaluate the appropriateness of a proposed design.
These barriers are likely to be enhanced in the coming years as the recent paradigm of
drug development involves a shift to more complex dose finding problems.
So the purpose of this talk is not to advocate the use of
any particular body of adaptive designs but to provide recommendations on
the minimal information that should be included in a protocol to
aid in the understanding and approval of the protocol by
the various scientific and regulatory committees
that review them and to provide guidance on what
should be included in order to appropriately conduct the actual protocol specific design.